Recent Advances in Omega-3 Fatty Acids to Reduce Risk of ASCVD in Patients With Elevated Triglyceride Levels

This activity was originally broadcast as a live virtual symposium during the 13th annual Directions in Pharmacy^® conference series.

Program Description
Elevated triglyceride levels increase cardiovascular (CV) risk in patients with well controlled low-density lipoprotein cholesterol levels and are part of the causal pathway of atherosclerosis. Statins are the current first-line treatment option; however, some patients are unable to tolerate statins or reduce their cholesterol with statin therapy alone. Omega-3 fatty acids are being incorporated into the treatment paradigm to reduce the residual risk in patients treated with statins. Pharmacists must be familiar with the latest clinical trial data, current and emerging treatments, and available omega-3 products to provide patient-specific therapy recommendations and education on reducing atherosclerotic CV disease risk. Through this activity, pharmacists will be equipped to proactively identify patients who may benefit from omega-3 fatty acid therapy to manage high triglyceride levels and effectively reduce atherosclerotic CV disease event risk.

Target Audience: Pharmacists

Type of Activity: Knowledge
Release date: June 21, 2023
Expiration date: June 21, 2024

Time to complete activity: 0.75 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Outline the role of omega-3 fatty acids in reducing atherosclerotic cardiovascular disease (ASCVD) event risk to optimize patient outcomes
• Articulate differences between commercially available omega-3 fatty acid products
• Review the latest clinical trial data and evidence-based guidelines, as well as their application to clinical practice for individualized treatment
• Elaborate on the role of the pharmacist in improving the care and outcomes in patients at high risk for ASCVD events, including providing treatment recommendations and patient education to reduce ASCVD risk

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hour (0.075 CEU) under the ACPE universal activity number 0290-0000-23-273-H01-P. The activity is available for CE credit through June 21, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, read the article in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Joseph Saseen, PharmD, BCPS, BCACP, CLS

Pharmacy Times Continuing Education^™ Planning Staff— Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta 

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms